MedPath

Factors that influence women*s utilization of prenatal screening for Down*s syndrome. Optimizing decision making and refining current and future screening policies by studying differences in uptake rates, between three European countries*

Completed
Conditions
Down syndrome
trisomy 21
10083624
10026908
Registration Number
NL-OMON38077
Lead Sponsor
niversitair Medisch Centrum Utrecht
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
112
Inclusion Criteria

Pregnant women:
- Participants should be older than 18, and confirmed pregnancy
- Good understanding of Dutch language
- Gestational age <10 weeks, 11-13 weeks and 14-20 weeks
- Singleton pregnancy
-

Exclusion Criteria

- Non pregnant women
- Pregnant women age < 18
- Former history of fetal anomalies
• Current pregnancy with fetal anomalies or maternal complications
• Pregnancy perceived by assisted reproductive technology

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The approach of the study will be a *mixed method*, also called a sequential<br /><br>exploratory approach, consisting of a review, desk research, completed with<br /><br>stakeholders interviews in the three countries, qualitative focus group<br /><br>discussions and semi-quantitative large-scale questionnaires.<br /><br>In this study, we are interested in participant*s reasons to decline or accept<br /><br>DSS. First, we want to determine which factors correlate with declining or<br /><br>accepting the test. As these data consider feelings, perceptions and<br /><br>interpretations of different levels, a qualitative approach is most suitable to<br /><br>provide this information. After we have determined discriminating factors of<br /><br>influence, we will perform large-scale questionnaires to determine if these<br /><br>findings are representative for large groups. Therefore a semi-quantitative<br /><br>approach is most applicable.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>NA</p><br>
© Copyright 2025. All Rights Reserved by MedPath